Chief Financial Officer, Head of Corporate Strategy, and Treasurer · Cartesian Therapeutics, Inc. (RNAC)

John Leaman

A named executive officer of Cartesian Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2018. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2018

$1,102,440

Salary $390,000Bonus $162,500

FY2017: $1,754,339

3rd of 4 named executive officers at Cartesian Therapeutics by FY2018 total.

4 named officers on file for Cartesian Therapeutics, FY2018

John Leaman’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 1 equity grant, each cited to its filing
  • RNAC’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Cartesian Therapeutics’s whole pay program stands against its peers

  • Cartesian Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on RNAC→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2019 (DEF 14A).

Free

Get John Leaman’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

John Leaman compensation by year

Cartesian Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Cartesian Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018
Salary$85,000$390,000
Bonus$32,500$162,500
Option awards$1,620,839$465,940
Pension and deferred compensation$0$0
All other$16,000$84,000
Total$1,754,339$1,102,440

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Cartesian Therapeutics, Inc. DEF 14A filed April 29, 2019, accession 0001453687-19-000043, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Cartesian Therapeutics, Inc. filed document, accession 0001453687-19-000043. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2019.

$1.8M
$1.1M
FY17
FY18
SalaryBonusOption awardsAll other

Equity holdings

unvested awards at FY2018 year-end
TypeUnvested unitsValue at year-endExercise price
Option50,000—$12.75
Option155,834—$10.23

Per the Outstanding Equity Awards at Fiscal Year-End table in Cartesian Therapeutics, Inc.'s FY2018 proxy; value at the fiscal year-end close, as the company printed it.

Cartesian Therapeutics’s named executive officers, FY2018

as the company reported each
Named executive officerRoleFY2018 total
Carsten BrunnPresident and Chief Executive Officer$5,605,148
Stephen SmolinskiChief Commercial Officer$1,236,950
John Leaman · this pageChief Financial Officer, Head of Corporate Strategy, and Treasurer$1,102,440
Werner CautreelsPresident and Chief Executive Officer$1,024,149

The full Cartesian Therapeutics compensation record

free company brief

This page is one person within Cartesian Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Cartesian Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Cartesian Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

John Leaman's compensation dossier · One-time report. No refunds.